New trial tailors anal cancer treatment for people with HIV
NCT ID NCT04929028
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether adjusting treatment based on risk level can improve outcomes for people with HIV who have anal cancer. Low-risk patients receive standard chemotherapy and radiation, while high-risk patients also get the immunotherapy drug nivolumab after standard treatment. The study will monitor side effects and cancer recurrence in 40 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- capecitabine, mitomycin, fluorouracil, nivolumab, intensity modulated radiation therapy
- What this could lead to
- If successful, this could lead to a more effective treatment plan that reduces the chance of anal cancer returning in people with HIV.
- What could go wrong
- This is a small, early-phase trial (40 participants) focused on safety and side effects, not yet proven to improve outcomes. Adding immunotherapy may increase side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AIDS-RELATED ANAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
George Washington University Medical Center
Washington D.C., District of Columbia, 20037, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Lyndon Baines Johnson General Hospital
Houston, Texas, 77026-1967, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Montefiore Medical Center - Moses Campus
The Bronx, New York, 10467, United States
-
Montefiore Medical Center-Einstein Campus
The Bronx, New York, 10461, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States
-
Mount Sinai West
New York, New York, 10019, United States
-
Pennsylvania Hospital
Philadelphia, Pennsylvania, 19107, United States
-
UT MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Illinois
Chicago, Illinois, 60612, United States
-
Virginia Mason Medical Center
Seattle, Washington, 98101, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Zuckerberg San Francisco General Hospital
San Francisco, California, 94110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immunotherapy drug boost the power of chemoradiation against anal cancer?
- Can a new strategy break the cycle of HIV care dropout?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Smart pill bottles and health coaches team up to tackle HIV in the deep south
- Can anal cancer treatment spare sexual well-being? a study tracks the toll over two years.
- Can one Mega-Dose of an antifungal beat a deadly infection in AIDS patients?